Ceftaroline fosamil: a new broad-spectrum cephalosporin.
about
Can we prevent antimicrobial resistance by using antimicrobials better?Disruption of Allosteric Response as an Unprecedented Mechanism of Resistance to AntibioticsTargeting Antibiotic ResistancePutting fungi to work: harvesting a cornucopia of drugs, toxins, and antibiotics.Changing needs of community-acquired pneumonia.Study of Antibiotic Resistance Pattern in Methicillin Resistant Staphylococcus Aureus with Special Reference to Newer Antibiotic.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaTriazole-Linked Glycolipids Enhance the Susceptibility of MRSA to β-Lactam Antibiotics.Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.Advances in the diagnosis and management of pediatric osteomyelitis.Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.Inhibitors targeting on cell wall biosynthesis pathway of MRSA.Development of new drugs for an old target: the penicillin binding proteins.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.Novel systemic antibiotics in dermatology.Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.Ampicillin and gentamicin are a useful first-line combination for the management of sepsis in under-five children at an urban hospital in Bangladesh.A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.Periprosthetic joint infections: clinical and bench research.Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus
P2860
Q26829707-1970C1F0-E402-4A28-A555-F411F1F322C6Q27684435-CAABC41B-567C-4850-8045-838F6400D634Q28078130-42026431-B7D9-4432-8CB1-A0594EA0EDF1Q35120203-41D639F2-D58E-4D50-AA38-D6BFACD53218Q35127530-B2D72446-6261-4A25-9D64-544D861A8C89Q35663379-722DDA60-7F92-438B-91D7-A19AAA31F8CAQ35752997-05A13776-BE17-4C98-909D-C89D89D24319Q35844514-2820208A-EECD-4B38-9D07-5846CE502B45Q37335859-96AC68DC-A068-4AA8-87BC-50FD3EAC944BQ37905654-F594CA2C-FE1D-4F66-BB32-327C94B0519BQ37982099-24A253A4-CD56-4C6E-B74D-4A323BF2B691Q38004886-0E4FF168-4D76-434D-83E6-F2803C6CA20AQ38035171-3FEC7EDE-FE24-4406-AEF5-FB80069A910CQ38055325-EAC284AC-89A5-40AE-BDAC-AF244293015BQ38117077-CB3C6F04-565B-4C48-9CBA-31549E413044Q38137920-FE922F50-FAB0-4A3F-811F-0F43074A3816Q39048083-1C692060-45B8-4038-9478-AC2E9424098AQ39616901-1230FBA8-92E5-4905-82AF-F4FEA89275FDQ39682573-74AE7A1A-6FE0-40A8-9951-8BDFBD122F18Q40084885-6AB73959-2816-49CD-9893-C0BD541B3625Q40360449-F338487B-8A77-4C24-9560-11DDF38A6A1AQ41907687-C9BBF266-4B99-49AC-A85A-358B57A35E6EQ41984202-014B1225-2CBF-49CA-80FF-39A6BE010653Q42788158-6DDED24C-D831-4B50-97BC-CAD97DC665F8Q45340895-91FC8641-0691-4BE0-B3B8-E3154F937B02Q50079038-F0CF4C98-6C17-4654-B96F-59658BE73E89Q50916931-7B62837F-94E0-425C-A58E-079FF0F7B28AQ53663173-CEB9A821-BA0E-494C-A19C-524C6C338983Q57210839-E8D8E5C5-1233-419C-A9E0-AF315EE1E955
P2860
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@en
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@nl
type
label
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@en
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@nl
prefLabel
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@en
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@nl
P2860
P356
P1476
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
@en
P2093
Joseph B Laudano
P2860
P304
P356
10.1093/JAC/DKR095
P407
P478
66 Suppl 3
P577
2011-04-01T00:00:00Z